The AstraZeneca and Daiichi Sankyo targeted cancer drug Enhertu is now the first therapy in its class approved for treating solid tumors regardless of either the cancer type or where the disease ...

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Monday that DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzum ...

AstraZeneca said on Monday a mid-stage trial of its cancer drug Enhertu, co-developed with Daiichi Sankyo, showed positive results across multiple HER2-expressing advanced solid tumours in heavily ...

Daiichi Sankyo and AstraZeneca finally have some clarity on the deaths that occurred in two phase 3 studies for their Enhertu follow up Dato-DXd.

AstraZeneca's cancer medicine Enhertu, a drug developed jointly with Japan's Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022.

In the Destiny Breast-09 study, AstraZeneca tested Enhertu plus Perjeta in patients with an advanced form of breast cancer. Perjeta is a common breast cancer treatment.

AstraZeneca, which is working on the drug with Japan's Daiichi Sankyo , opens new tab, said on Monday that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with ...

AstraZeneca PLC and Daiichi Sankyo Co. said Friday that Enhertu has been granted orphan drug designation in the U.S. for patients with gastric cancer. The U.K. drug maker said that the U.S. Food ...

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

AstraZeneca and Daiichi Sankyo are rapidly gaining traction for their Enhertu in HER2-positive breast cancer. Next up? An early chance at expanding the blockbuster-to-be into a tough-to-treat ...

AstraZeneca, which is working on the drug with Japan's Daiichi Sankyo 4568.T, said on Monday that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with low levels ...